Incretin Hormone Antagonism After Bariatric Surgery
- Conditions
- Bariatric Surgery
- Registration Number
- NCT03950245
- Lead Sponsor
- Hvidovre University Hospital
- Brief Summary
Using the glucagon-like peptide-1 (GLP-1) antagonist exendin(9-39) and the glucose-dependent insulinotropic peptide (GIP) antagonist GIP(3-30), the purpose of this study is to clarify the importance of endogenous GLP-1 and GIP for postprandial glucose metabolism after RYGB and SG in subjects with normal glucose tolerance. We hypothesize that GLP-1 is more important after RYGB, and GIP is more important after SG, for postprandial glucose tolerance and beta-cell function. A group of un-operated subjects with normal glucose tolerance will serve as controls.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Not provided
- Thyrotoxicosis or inadequately treated hypothyreosis
- Hemoglobin < 6.5 mmol/l at inclusion
- Pregnancy or breast feeding
- Medication affecting the planned examinations
Matching between groups
- Age
- Sex
- BMI at inclusion and for surgery groups also pre-surgery BMI
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method iAUC glucose 240 minutes Main comparison between groups: delta iAUC glucose (iAUC exendin(9-39) test day - iAUC GIP(3-30) test day) in the RYGB group compared to the SG group
- Secondary Outcome Measures
Name Time Method Beta-cell glucose sensitivity (β-GS) 240 minutes Main comparison between groups: delta β-GS (β-GS exendin(9-39) test day - β-GS GIP(3-30) test day) in the RYGB group compared to the SG group
Trial Locations
- Locations (2)
Department of Endocrinology
🇩🇰Hvidovre, Denmark
Hvidovre Hospital
🇩🇰Hvidovre, Denmark
Department of Endocrinology🇩🇰Hvidovre, Denmark